Clinical remission with biologic therapies in severe asthma: a matter of definition
Extract
Personalised medicine for treatment of severe asthma using relevant biologic therapies to target specific asthma phenotypes can be considered a major advance in disease management [1]. Agents that target eosinophilic inflammation, for example by interrupting the interleukin (IL)-5 pathway in patients with severe eosinophilic asthma, can halve the rate of severe asthma exacerbations [2]. It is possible that these agents influence the natural history of particular asthma phenotypes, potentially inducing disease remission (figure 1).
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Beasley, R., Noble, J., Weatherall, M. Tags: Editorials Source Type: research
More News: Asthma | Respiratory Medicine